

Post-Marketing Clinical Follow-Up Trial to Evaluate the Performance and Safety of the Medical Device 047 TD Dermatitis Cream in Adults and Children With Atopic and Contact Dermatitis Symptoms Confirmed by Clinical Parameters

NCT07056569

Status	RECRUITING
Phase	Not Applicable
Sponsor	Biokosmes Srl
Enrollment	90 participants

Key Eligibility Criteria

Inclusion (5)

- Male/ female \> 6 months \< 65 years
- Patient diagnosed AD/CD
- Patient with EASI max \<16
- Patient with IGA 1-3
- Patient in good condition with no serious systemic disease

Exclusion (8)

- Hypersensitivity to any 047_TD Dermatitis cream ingredients
- Any other skin disease at the target area that would interfere the clinical assessment in the opinion of the investigator
- Any other adjuvant therapy for AD/CD (UV therapy, probiotics, homeopathy etc.) within 30 days before Baseline as well as during the entire study
- Any use of another topical emollient or other established treatment for AD/CD during the study at the site of flares (AD/CD lesions). Exception are usual hygienic products in the diaper area
- A history of currently undergoing immunosuppressive drug therapy, chemotherapy, or radiation therapy
- ... and 3 more (see full listing online)

Locations (3 total)

Studio Medico Pigatto Bersani, Milan, Italy
Poliambulatorio Verona, Verona, Italy
Studio Medico, Voghera, Italy

<https://clinicaltrials.gov/study/NCT07056569>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).